ePrints

Treatment of osteoporosis in women intolerant of oral bisphosphonates.

Lookup NU author(s): Dr Terry AsprayORCiD, Emeritus Professor Roger Francis

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

In the past 15 years, oral bisphosphonate therapy has become the mainstay of pharmacological management in patients with osteoporosis. In the UK, alendronate is the drug of first choice, based on clinical efficacy data and cost. However, some patients are unable to take oral bisphosphonates for a number of reasons. In this article, we review the practical management of such cases, including strategies for monitoring adherence and switching to alternative oral agents (e.g. risedronate, strontium ranelate, raloxifene). In some cases, alternative parenteral agents may be considered, including intravenous bisphosphonates, parathyroid hormone therapies and denosumab. Specific concerns about safe prescribing are considered, when prescribing potent anti-resorptive medications, particularly relating to renal function and vitamin D deficiency. Finally, consideration is given to clinical risk factors, including aspects of lifestyle which may be modified to decrease fracture risk. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

Publication metadata

Author(s): Francis RM; Aspray TJ

Publication type: Review

Publication status: Published

Journal: Maturitas

Year: 2012

Volume: 71

Issue: 1

Pages: 76-78

Print publication date: 10/11/2011

ISSN (print): 0378-5122

ISSN (electronic): 1873-4111

Publisher: ELSEVIER IRELAND LTD

URL: http://dx.doi.org/10.1016/j.maturitas.2011.10.005

DOI: 10.1016/j.maturitas.2011.10.005

PubMed id: 22079368

Share